This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Medtronic (MDT) Progresses in SNM With Updated InterStim Label
by Zacks Equity Research
Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.
Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q4.
Ecolab's (ECL) Certified Program to Build Customer Confidence
by Zacks Equity Research
Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater
by Zacks Equity Research
Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
by Zacks Equity Research
The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.
Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry
by Zacks Equity Research
Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.
New Study Favors Myriad Genetics' (MYGN) GeneSight Test
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.
Align Technology (ALGN) Beats on Q4 Earnings, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.
The Cooper Companies (COO) Unit Gets a Boost From New Buyout
by Zacks Equity Research
The Cooper Companies (COO) arm's buyout drives its growing portfolio of medical products, which revolves around clinic and practice-based women's healthcare
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 40.56% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
by Zacks Equity Research
Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.
MedTech Stock Earnings on Feb 2: IDXX, MCK & More
by Urmimala Biswas
In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.